Notably, TAF1 mutations occur in over 20% of uterine corpus endometrial carcinoma (UCEC) samples, a frequency that correlates with decreased progression-free survival in this cohort, suggesting TAF1 as a candidate biomarker and potential therapeutic target in endometrial cancer. Here, TAF1 is linked to uterine corpus endometrial carcinoma.